Clinical trial
A Phase 2, Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone as Second Line Therapy in Multiple Myeloma Patients Who Have Received Prior Treatment With a Lenalidomide Based Regimen
NCT03746652 is registered in ClinicalTrials.gov with Hellenic Society of Hematology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone as Second Line Therapy in Multiple Myeloma Patients Who Have Received Prior Treatment With a Lenalidomide Based Regimen
- Lead sponsor
- Hellenic Society of Hematology
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 31, 2018
- Completion date
- December 31, 2021
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.